Alkermes v. Slayback Pharma: Meloxicam Injection Dispute Settled With Prejudice
Alkermes PLC brought a five-patent infringement action against Slayback Pharma LLC and Slayback Pharma India LLP in the District of New Jersey, asserting IP rights over a meloxicam injection formulation dosed at 30 mg/mL. The case concluded via a settlement agreement and stipulated dismissal with prejudice after 305 days, with each party bearing its own costs and fees.
Five-Patent Meloxicam Formulation Dispute Ends in Prejudicial Settlement
Alkermes PLC filed suit on 14 July 2023 in the U.S. District Court for the District of New Jersey against Slayback Pharma LLC and its Indian affiliate Slayback Pharma India LLP. The complaint alleged infringement of five U.S. patents — US10881663B2, US11458145B2, US10471067B2, US10709713B2, and US10463673B2 — all directed to meloxicam injection formulations at a concentration of 30 mg/mL and a 30 mg dose, a product in the injectable NSAID space.
The parties reached a settlement agreement and filed a stipulated dismissal on 14 May 2024 pursuant to Rule 41 of the Federal Rules of Civil Procedure. All claims, counterclaims, and defenses were dismissed with prejudice. The with-prejudice designation means Alkermes cannot re-file these specific infringement claims against Slayback for the same accused product, while Slayback’s counterclaims — which may have included invalidity challenges — are also extinguished. Each side bears its own legal costs.
The 305-day duration suggests the parties moved to resolution before claim construction or substantive merits briefing, consistent with a negotiated market-access arrangement. The public record does not disclose the commercial terms of the underlying settlement, so whether Slayback secured a license, agreed to a delayed launch date, or accepted other restrictions on its meloxicam injection product remains unknown. The mutual cost-bearing provision is a standard hallmark of negotiated pharmaceutical patent settlements.
Filing to Dismissed with Prejudice in 305 days
305 days from filing to dismissal — shorter than the median ANDA/NDA patent case in D.N.J.
Dismissed with prejudice: what the settlement stipulation means for both parties
Rule 41 stipulated dismissal with prejudice explained
Under Federal Rule of Civil Procedure 41, parties may jointly stipulate to dismiss an action. A dismissal ‘with prejudice’ operates as a final adjudication on the merits, permanently barring Alkermes from re-asserting the same infringement claims against Slayback for this product. It also extinguishes any counterclaims Slayback raised, typically including patent invalidity defences.
Merits-barring dismissalAlkermes surrenders re-filing rights — but likely secured commercial terms
By agreeing to a with-prejudice dismissal, Alkermes accepted that it cannot re-litigate these infringement claims against Slayback on the same product. In pharmaceutical patent practice, this is typically accompanied by a private settlement agreement that may include a licensed launch date or market-sharing arrangement — the commercial substance is not on the public record.
Private settlement likelySlayback’s invalidity counterclaims also dismissed — validity record preserved
The with-prejudice dismissal extinguishes Slayback’s counterclaims, including any invalidity challenge it may have asserted. This means the five Alkermes meloxicam patents survive without a court ruling on their validity. Slayback cannot re-litigate invalidity in this venue, though IPR petitions at the USPTO would represent a separate avenue if not contractually barred by the settlement.
No invalidity ruling on recordNo validity ruling strengthens Alkermes’ position against future generic challengers
Because the case settled before any claim construction or merits ruling, all five meloxicam injection patents emerge untested by the courts. Future generic entrants face the same patent wall without the benefit of any Slayback-generated invalidity record. This outcome is consistent with Alkermes maintaining a strong exclusivity posture in the injectable meloxicam segment pending any further ANDA challenges.
Patents remain unchallenged in courtFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Alkermes, PLC | Company | Specialty pharmaceutical company — holder of US10881663B2 and related meloxicam injection patentsSearch in Eureka ↗ |
| Defendant | Slayback Pharma, LLC | Company | Generic pharmaceutical developer (U.S. and India entities) seeking entry into the meloxicam injection marketSearch in Eureka ↗ |
| Co-Defendant | Slayback Pharma India, LLP | Company | Search in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for Alkermes, PLCSearch in Eureka ↗ |
| Plaintiff counsel | Michael V. Caracappa | Attorney | Counsel for Alkermes, PLCSearch in Eureka ↗ |
| Plaintiff counsel | Tyler Doh | Attorney | Counsel for Alkermes, PLCSearch in Eureka ↗ |
| Plaintiff counsel | VISHAL CHANDRA GUPTA | Attorney | Counsel for Alkermes, PLCSearch in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Alkermes, PLCSearch in Eureka ↗ |
| Plaintiff law firm | Steptoe, LLP | Law Firm | Representing Alkermes, PLCSearch in Eureka ↗ |
| Defendant counsel | Andrew J. Miller | Attorney | Counsel for Slayback Pharma, LLCSearch in Eureka ↗ |
| Defendant law firm | Windels Marx Lane & Mittendorf, LLP | Law Firm | Representing Slayback Pharma, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal references ‘a settlement agreement between the parties’ as the operative trigger, confirming that the with-prejudice disposition reflects a negotiated resolution rather than a litigation defeat for either side. The language extinguishing ‘all claims, counterclaims, and defenses’ is notably comprehensive, suggesting the parties intended a clean break with no surviving litigation rights in this forum. The absence of any court-adjudicated merits ruling means the validity and infringement posture of the five meloxicam patents remains legally unchanged.
US10881663B2 — Meloxicam injection formulation, 30 mg/mL
The five asserted patents — US10881663B2, US11458145B2, US10471067B2, US10709713B2, and US10463673B2 — protect Alkermes’ proprietary formulation of meloxicam for parenteral injection at a 30 mg/mL concentration. Meloxicam is a COX-2-selective NSAID; injectable formulations are clinically significant for acute post-operative pain management where oral administration is impractical. The application filings span US15/437534 through US16/550239, reflecting a continuation-family strategy designed to extend and layer protection across formulation, dosing, and manufacturing dimensions.
The breadth of a five-patent continuation family around a single injectable product signals that Alkermes has pursued aggressive claim diversification — a common strategy in branded pharmaceutical IP to create overlapping exclusivity that outlasts any single patent. For generic manufacturers, this structure means that successfully invalidating one family member does not open the market; all five must be addressed. The commercial stakes are substantial: injectable NSAIDs with a defined dosing profile serve a large post-surgical hospital market where branded pricing is most defensible.
Should you run an FTO against the Alkermes meloxicam injection patent family?
Any company developing, formulating, or seeking regulatory approval for a generic or biosimilar meloxicam injection product at or near the 30 mg/mL concentration should treat these five patents as active blocking rights. The Slayback case confirms Alkermes is willing to assert all five patents simultaneously — and that a pre-clearance settlement may involve significant commercial obligations. R&D and regulatory teams should not proceed to ANDA filing without a documented FTO opinion covering the full continuation family.
PatSnap Eureka’s FTO Search Agent can map each of the five asserted patents against your formulation parameters, identify prior art bearing on validity, and surface any continuation applications still pending in the family. Given the layered nature of Alkermes’ meloxicam portfolio, automated claim charting across multiple family members is essential — Eureka can accelerate that analysis from weeks to hours, enabling your IP team to prioritise design-around opportunities or IPR petition targets before committing to development resources.
Run a freedom-to-operate analysis on US10881663B2 to assess your product’s exposure
Run FTO in Eureka →Similar injectable pharmaceutical patent cases in D.N.J. and Hatch-Waxman disputes
Explore comparable ANDA-related infringement actions involving injectable NSAID or small-molecule formulation patents litigated in the District of New Jersey.
What this case signals for the injectable NSAID patent landscape
A five-patent settlement with prejudice in D.N.J. before claim construction sends clear signals to other generic aspirants in the meloxicam injection space.
Pre-claim-construction settlements preserve the full patent portfolio intact
Alkermes resolved this dispute before any judicial scrutiny of its five meloxicam patents. No adverse claim construction, no invalidity ruling. For competitors monitoring this space, those patents carry the same scope and presumption of validity as on filing day — a significant enforcement advantage Alkermes retains.
With-prejudice term signals a structured agreement, not a walk-away
Generic pharmaceutical settlements under Hatch-Waxman typically involve a negotiated authorised entry date or royalty arrangement in exchange for dismissal with prejudice. The mutual cost-bearing clause and with-prejudice designation here are consistent with that template, suggesting Slayback’s market access is now contractually managed rather than blocked outright.
Alkermes v Slayback — key questions answered
Alkermes asserted five U.S. patents: US10881663B2, US11458145B2, US10471067B2, US10709713B2, and US10463673B2. All five relate to meloxicam injection formulations at 30 mg/mL and form a continuation patent family filed across application numbers US15/437534 through US16/550239.
Dismissal with prejudice under Rule 41 permanently bars Alkermes from re-filing the same infringement claims against Slayback for the same meloxicam injection product. It also extinguishes Slayback’s counterclaims — which likely included invalidity challenges — meaning the five patents survive the litigation without any adverse validity ruling on record.
No. The case was dismissed by stipulation before any substantive merits ruling, including claim construction or invalidity determinations. The five asserted patents remain presumptively valid and fully enforceable. The court made no findings on infringement or invalidity.
The case lasted 305 days, from filing on 14 July 2023 to dismissal on 14 May 2024. This duration is relatively short for a five-patent pharmaceutical infringement action in D.N.J., suggesting the parties negotiated a resolution before reaching major litigation milestones such as claim construction hearings.
The accused product is Slayback’s meloxicam injection at a concentration of 30 mg/mL, administered at a dose of 30 mg. This is a parenteral NSAID formulation used primarily for acute pain management. Alkermes holds the branded injectable meloxicam franchise and alleged that Slayback’s generic version infringed its five-patent portfolio.
PatSnap Eureka searches patents and litigation data to answer instantly.